Wells Fargo Adjusts Price Target on Aeglea BioTherapeutics to 0.50 From 0.35, Maintains Equal-Weight Rating - Marketscreener.com
AGLEDelisted Stock | USD 0.59 0.01 1.72% |
About 54% of Aeglea Bio's shareholders are presently thinking to get in. The analysis of current outlook of investing in Aeglea Bio Therapeutics suggests that some traders are interested regarding Aeglea Bio's prospects. The current market sentiment, together with Aeglea Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use Aeglea Bio Therapeutics stock news signals to limit their universe of possible portfolio assets.
Aeglea |
Wells Fargo Adjusts Price Target on Aeglea BioTherapeutics to 0.50 From 0.35, Maintains Equal-Weight Rating Marketscreener.com
Read at news.google.com
Aeglea Bio Fundamental Analysis
We analyze Aeglea Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aeglea Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aeglea Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Aeglea Bio is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Aeglea Bio Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aeglea Bio stock to make a market-neutral strategy. Peer analysis of Aeglea Bio could also be used in its relative valuation, which is a method of valuing Aeglea Bio by comparing valuation metrics with similar companies.
Peers
Aeglea Bio Related Equities
TIL | Instil Bio | 16.79 | ||||
ASMB | Assembly Biosciences | 10.72 | ||||
ALRN | Aileron Therapeutics | 7.03 | ||||
CTMX | CytomX Therapeutics | 6.25 | ||||
NUVB | Nuvation Bio | 3.21 | ||||
XLO | Xilio Development | 2.02 | ||||
SNTI | Senti Biosciences | 1.42 | ||||
EWTX | Edgewise Therapeutics | 0.37 | ||||
IKNA | Ikena Oncology | 1.17 | ||||
BNTC | Benitec Biopharma | 1.22 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
DSGN | Design Therapeutics | 2.93 | ||||
CING | Cingulate | 3.67 | ||||
BPTH | Bio Path | 3.75 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |